



OPEN ACCESS

EDITED BY

Sharon Chiang,
University of California, San Francisco,
United States

REVIEWED BY

Luis Rafael Moscote-Salazar,
Colombian Clinical Research Group in
Neurocritical Care, Colombia
Umberto Aguglia,
University Magna Graecia, Italy

*CORRESPONDENCE

Yuki Kawamura
✉ yuki.kawamura@yale.edu
Nishant K. Mishra
✉ nishant.mishra@yale.edu

RECEIVED 19 September 2025

REVISED 25 November 2025

ACCEPTED 15 December 2025

PUBLISHED 08 January 2026

CITATION

Kawamura Y, Trinko E, Quinn TJ, Emsley HCA,
Zelano J, Tanaka T, Ihara M, Sansing LH,
Liebeskind DS and Mishra NK (2026)
Pharmacological strategies for preventing
post-stroke seizures and epilepsy.
Front. Neurol. 16:1709077.
doi: 10.3389/fneur.2025.1709077

COPYRIGHT

© 2026 Kawamura, Trinko, Quinn, Emsley,
Zelano, Tanaka, Ihara, Sansing, Liebeskind and
Mishra. This is an open-access article
distributed under the terms of the [Creative
Commons Attribution License \(CC BY\)](#). The
use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Pharmacological strategies for preventing post-stroke seizures and epilepsy

Yuki Kawamura^{1,2*}, Eugen Trinko^{3,4,5}, Terence J. Quinn⁶,
Hedley C. A. Emsley⁷, Johan Zelano^{8,9,10}, Tomotaka Tanaka^{11,12},
Masafumi Ihara¹¹, Lauren H. Sansing¹, David S. Liebeskind¹³ and
Nishant K. Mishra^{1*}

¹Department of Neurology, Yale School of Medicine, New Haven, CT, United States, ²School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom, ³Department of Neurology, Center for Cognitive Neuroscience, Christian Doppler University Hospital, Paracelsus Medical University, Member of the ERN EpiCARE, Salzburg, Austria, ⁴Neuroscience Institute, Center for Cognitive Neuroscience, Christian Doppler University Hospital, Paracelsus Medical University, Salzburg, Austria, ⁵Karl Landsteiner Institute for Clinical Neuroscience, Salzburg, Austria, ⁶School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom, ⁷Lancaster Medical School, Lancaster University, Lancaster, United Kingdom, ⁸Institute of Neuroscience and Physiology, Department of Clinical Neuroscience, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁹Wallenberg Center of Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden, ¹⁰Department of Neurology, Sahlgrenska University Hospital, Member of the ERN EpiCARE, Gothenburg, Sweden, ¹¹Department of Neurology, National Cerebral and Cardiovascular Center, Osaka, Japan, ¹²Department of Neurology, Faculty of Medicine, Shimane University, Izumo, Japan, ¹³Department of Neurology, University of California Los Angeles, Los Angeles, CA, United States

Stroke is the most common cause of new-onset seizures and epilepsy in the older population, which is associated with increased morbidity and mortality. Post-stroke seizures (PSS) are traditionally divided into early and late seizures, occurring before and after 7 days post-stroke, respectively. A single late seizure is sufficient to diagnose post-stroke epilepsy. This narrative review discusses approaches to diagnosing and treating PSS, as well as the various pharmacological agents available. Although current evidence is limited, we suggest that levetiracetam and lamotrigine may be preferred agents for preventing acute seizure recurrence. Statins, GLP-1 agonists, eslicarbazepine, perampanel, and losartan have not been evaluated yet and need further study on their ability to prevent first-time seizures in stroke patients. While clinical trials of antiseizure medications can be costly, further research into biomarkers of epileptogenesis could facilitate more feasible clinical trials to enhance the evidence base for antiseizure medications in post-stroke seizures and epilepsy.

KEYWORDS

stroke, post-stroke epilepsy, seizures, stroke outcome, cerebral haemorrhage, antiseizure medication

1 Introduction

Cerebrovascular disease accounts for nearly 50 % of new-onset seizures and epilepsy in individuals over 65 years of age (1). Post-stroke seizures (PSS) are linked with increased morbidity, mortality, and cognitive impairment compared to those without. Early recognition and treatment of PSS are therefore crucial steps in reducing the disease burden of stroke, but existing literature on its pharmacological management remains limited (2–4). Importantly, current therapies for PSS usually control seizures but do not address the underlying disease process, and no treatment has yet been demonstrated to prevent the development of epilepsy after a stroke in humans (5, 6). There is a critical need to develop anti-epileptogenesis strategies

for the primary prevention of PSS that target the underlying disease mechanism, as well as to identify effective medications for preventing seizure recurrence (7). In this narrative review, we summarise the current evidence regarding diagnostic and treatment approaches for PSS, along with the effectiveness, safety, and drug–drug interactions of ASMs.

2 Definitions and diagnostic approach

Key terms and definitions are described in Table 1. PSS can be subdivided, depending on the time before onset, into early post-stroke seizures (EPSS), which occur less than 7 days after stroke, and late post-stroke seizures (LPSS), which occur after a week. Unlike EPSS, which are considered provoked seizures due to toxic or metabolic effects of stroke, LPSS can be considered as unprovoked seizures (8). LPSS are associated with a higher risk of seizure recurrence than EPSS (10-year recurrence risk of 65% vs. up to 33%, respectively (9–11)). The International League Against Epilepsy (ILAE) definition of epilepsy includes “one unprovoked (or reflex) seizure and a probability of further seizures similar to the general recurrence risk (at least 60%) after two unprovoked seizures, occurring over the next 10 years” (12); hence, one LPSS is sufficient to diagnose *post-stroke epilepsy (PSE)*.

Current clinical definitions of PSS in effect utilise time between the stroke and seizure as a proxy to infer whether the seizure episode is due to direct injury from stroke (EPSS) or the likely presence of underlying epileptogenic changes (LPSS). However, the temporal course of epileptogenesis is likely to be more nuanced (13). Indeed, a study demonstrated that patients with PSS 4–7 days after a stroke are more likely to develop PSE compared to those with seizures within 3 days (14), suggesting that changes conferring longer term seizure risk can commence even within the first week. Interestingly, a more recent multicentre study on 4,552 patients found that seizures on the day of the stroke was associated with a higher risk of PSE compared to EPSS after 1 day (15), again implying pathophysiological changes occurring very early after stroke onset can influence the risk of PSE. In particular, patients with focal to bilateral tonic–clonic seizures on the day of stroke had a 69% 10-year risk of LPSS, exceeding the risk threshold used in the ILAE definition of epilepsy, although they would not qualify as having epilepsy since EPSS are currently considered as acute symptomatic (or provoked) seizures. Towards the other end of the time spectrum of late seizures, new-onset seizures occurring more than 2 years after stroke have a lower recurrence risk than late seizures occurring within the first 2 years (16). Together, these findings demonstrate that time from stroke to first seizure fails to capture the full complexity of epileptogenic changes after a stroke. As most seizure recurrences after EPSS occur within 1–2 years (17), with risk declining sharply thereafter, we need more dynamic tools, such as the Chance of an Occurrence of a Seizure in the Next Year (COSY) and validated prognostic models, such as the SeLeCT 2.0 (18) and CAVE scores (19).

Multimodal approaches integrating EEG monitoring can further boost predictive capability and have been incorporated in scoring systems such as the SeLeCT-EEG score for risk prediction after ischaemic stroke (20). These integrative approaches can aid rationalised

TABLE 1 Key terms and definitions.

Term	Definition
Post-stroke seizures (PSS)	Seizures observed in patients after a stroke
Acute symptomatic seizures	Seizures occurring at time of or close temporal association with a brain insult ¹
Early Post-Stroke Seizures (EPSS)	Seizures observed in patients within 7 days of a stroke
Late Post-Stroke Seizures (LPSS)	Seizures observed in patients after 7 days post-stroke
Post-Stroke Epilepsy (PSE)	Unprovoked late post-stroke seizures
Primary prevention	Administration of pharmacotherapy to prevent epileptogenic abnormalities
Primary prophylaxis	Administration of pharmacotherapy to prevent the incidence of seizures, without necessarily modifying the underlying epileptogenic abnormality
Secondary prophylaxis	Administration of pharmacotherapy to prevent recurrence of seizures in patients who have already had a post-stroke seizure, without necessarily modifying the underlying epileptogenic abnormality

¹ Beghi et al. (137).

PSE treatment, as demonstrated in a decision analysis study which found that using a risk-guided approach to pharmacological treatment guided by an EEG-based risk stratification tool can improve outcomes in certain clinical scenarios (21). Interictal epileptiform discharges in PSE patients also independently predict recurrence of seizures (22), lending further support to the utility of tools that are able to capture richer physiological parameters suggestive of epileptogenesis.

In view of these findings, a tissue-based (in contrast to time-based) approach to diagnosing PSE has recently been proposed (23). While there is currently no consensus for such an approach, a proposed tissue-based diagnostic approach to PSE starts with the assessment of epileptiform discharges or active biological biomarkers. Following clinical evaluation, the initial investigation consists of using an electroencephalogram (EEG) to assess for the presence of interictal discharges and seizure patterns (Figure 1). The presence of hallmark epileptic features on EEG leads to the diagnosis of PSE. Alternatively, biomarkers have been proposed to assess epileptogenesis (5). Although reliable biomarkers have not yet been established, once discovered, they will likely contribute to tissue-based PSE definitions (23). Status epilepticus in EPSS has been identified as a risk factor for PSE (15, 24) and could be a potential candidate for a biomarker, but it is yet unclear whether this indicates actual epileptogenicity or is simply associated with a higher risk of epileptogenesis. In the absence of hallmark EEG features or biomarkers, hyperperfusion in the affected regions identified by imaging modalities such as diffusion-weighted imaging (DWI), CT perfusion (CTP), arterial spin labelling (ASL)-MRI, or SPECT (25, 26) during the ictal phase can indicate probable PSE. If ictal imaging findings do not indicate hyperperfusion, the presence of hallmark seizure features on postictal EEG or hypoperfusion on postictal SPECT can point towards a probable diagnosis of PSE. While neuroimaging can provide valuable insights

Abbreviations: ASM, antiseizure medication.

Diagnostic flow chart for post-stroke epilepsy




FIGURE 1

Schematic of clinical approach to post-stroke seizures. Used with kind permissions of Drs Tomotaka Tanaka, Masafumi Ihara, and Kazuki Fukuma (IED: Interictal epileptic discharges).

into underlying epileptogenic changes, hyperperfusion changes are not always concordant with EEG-based localisation (27, 28), and ambiguity also remains whether other imaging findings associated with epilepsy are specific signs of epileptogenesis or artefacts of the initial insult (29, 30). Diagnosis of PSE currently remains clinical, and further refinement of imaging criteria are needed before they can be used as reliable markers of epilepsy.

3 Pathophysiology

The process of epileptogenesis can be considered as a cascade of pathobiological processes which reduces the seizure threshold (illustrated in green in Figure 2) to a level at which seizures can occur in response to precipitating factors (Figure 2A). The purpose of primary prevention is to prevent epileptogenic processes from progressing and maintain a seizure threshold high enough to prevent spontaneous seizures from occurring (Figure 2B) (31). An ideal approach would be to eliminate the effects of epileptogenic mechanisms so that an underlying abnormality does not develop. Primary and secondary prophylaxis also aim to increase the seizure threshold so that no seizures occur for the first time or recur after an episode, respectively, but without necessarily modifying the underlying epileptogenic abnormality (Figures 2C,D).

EPSS and LPSS are widely considered to have distinct pathophysiological mechanisms, albeit with imperfect separation

and some evidence, as alluded to above, of overlap. The pathogenesis of EPSS has generally been attributed to excitotoxicity due to ion channel dysfunction, reduction of seizure threshold due to attenuation of GABAergic signalling, elevated cortisol concentration causing neurotoxicity, and haemosiderin deposits leading to increased oxidative stress (32). Conversely, the pathogenesis of LPSS is associated with gliotic scarring secondary to persistent inflammation, epileptogenic pathways that follow blood–brain barrier disruption, and related changes to neuronal networks (33, 34). In regions with blood–brain barrier disruption, blood-derived albumin can bind to the transforming growth factor- β receptor and reduce astrocytes' uptake of potassium ions and glutamate, resulting in a lower seizure threshold (32).

In addition to the differences in pathophysiology, EPSS and LPSS are also associated with different risk factors for recurrence. Status epilepticus and male sex were associated with an increased risk of recurrence in patients with EPSS, whereas younger age was associated with increased seizure recurrence in those with LPSS (10, 35). The epidemiology of PSS is also affected by the inciting aetiology. PSS are more common in intracerebral (ICH) or subarachnoid haemorrhage (SAH) in comparison to ischaemic stroke (incidence rate of 10–16% vs. 3–6% in the acute phase) (36, 37). Haemosiderin deposition, blood–brain barrier disruption, and cortical superficial siderosis are strongly associated with seizure induction (23), which is consistent with the higher PSS risk observed




FIGURE 2

Schema of epileptogenesis (A), primary prevention (B), primary prophylaxis (C), and secondary prophylaxis of seizures (D). Adapted from Engel et al. (11) with permission from the publisher. Epileptogenesis is considered a cascade of several pathogenic mechanisms (illustrated as M1, M2, and M3) combining to create an epileptogenic abnormality. Once the seizure threshold (in light green) goes below a certain level (dotted line), seizures can occur spontaneously or in response to precipitating factors.

in patients with ICH, SAH or ischaemic stroke with haemorrhagic transformation (38). Hence, both the timing of PSS and inciting stroke subtype are likely to be relevant considerations in pathogenic mechanisms targeted in pharmacotherapy. The current review includes a summary of studies performed specifically for ischaemic stroke or ICH and SAH cohorts.

4 Pharmacology

4.1 ASMs for primary and secondary prophylaxis

4.1.1 First-generation ASMs

4.1.1.1 Clinical effectiveness

First-generation ASMs include agents that act on voltage-gated sodium channels, such as phenytoin and carbamazepine, agents that act on GABA_A receptors, such as phenobarbital and diazepam, and

agents such as valproic acid whose mechanisms have not yet been fully elucidated (39).

A Cochrane Review on ASMs for primary PSS prophylaxis published in 2022 identified two randomised control trials, both of which involved first-generation ASMs (valproic acid and diazepam). It concluded that ASMs were not shown to be effective in primary prophylaxis of PSS (40). The first trial administered valproic acid orally with an initial loading dose of 400 mg twice daily, then adjusted to maintain a mild therapeutic dose (50–100 µg/dL) to 72 patients. The study failed to find a significant difference in the incidence of EPSS (2.7% vs. 11.1%, treatment vs. placebo, respectively) and LPSS (16.6% vs. 11.1%) between valproic acid and placebo, but observed better neurological outcomes after 12 months in the treatment group (41). The second trial compared treatment with diazepam 10 mg rectally as soon as possible after stroke, followed by 12-hourly therapy for 3 days or earlier until discharge with a placebo in 784 patients. The trial reported no significant difference in seizure occurrence in either group (1.5 vs. 3.3%, treatment vs. placebo, respectively), but the results achieved

significance in favour of treatment if restricted to patients with cortical infarcts in the anterior circulation (42).

Neither study reported results on secondary prophylaxis of EPSS or LPSS. A retrospective cohort study of 3,622 people with PSS based on the national insurance database in Taiwan demonstrated that hospitalisation for seizure recurrence was highest in patients taking phenytoin and higher in those taking valproic acid and carbamazepine in comparison to newer ASMs (43). In summary, there is limited evidence to suggest that first-generation ASMs are effective for primary and secondary prophylaxis of PSS.

4.1.1.2 Safety/tolerance

Valproic acid has been associated with thrombocytopaenia in 5–18% of general adult patient cohorts, manifesting in prolonged bleeding time, abnormality in platelet laboratory values, or petechiae (44). This effect has been replicated *ex vivo* in blood samples from patients treated with valproic acid, which resulted in decreased platelet aggregation (45) as well as in blood collected from an animal model exposed to valproic acid and haemorrhagic shock, which resulted in significantly reduced platelet aggregation, clot strength, and clot formation rate (46). Modelling the risk of thrombocytopaenia demonstrated that female sex, high trough free valproic acid levels, and baseline platelet counts are associated with increased risk of thrombocytopaenia in patients administered valproic acid (47). Potential effects on coagulation properties could complicate prescription of valproic acid in conjunction with anticoagulants in stroke survivors with high clotting risk. In addition, a particular concern in older patients is the risk of valproate encephalopathy, a syndrome not yet fully understood that can include cognitive decline, brain atrophy, tremor/parkinsonism (16, 48).

Some first-generation ASMs have relatively higher risks for foetal malformations when used in pregnancy. Valproic acid is associated with major malformations and a 1–3% risk of neural tube defects (49), and is therefore contraindicated in women and girls of childbearing potential, with avoidance also advised in men (MHRA, CHM advice), although the strength of advice can vary, such as in Japan (50). Phenytoin is associated with foetal hydantoin syndrome in around 11% of children exposed *in utero*, with an additional 30% of exposed children expressing some of the pathological features (51).

4.1.1.3 Drug–drug interactions

Valproic acid is involved in several drug–drug interactions by inhibiting the metabolism of other medications. For example, valproic acid increases the half-life of lamotrigine two- to three-fold and is also known to increase serum concentrations of phenobarbital, phenytoin, carbamazepine, and rufinamide (52). Dose adjustments might be necessary when valproic acid is added to the pharmacological regimen to minimise potential side effects.

Many first-generation ASMs can alter the pharmacokinetics of direct oral anticoagulants (DOACs) through induction of cytochrome enzymes and P-glycoprotein. This is a relevant consideration given that 1.4% of patients on DOACs also take cytochrome enzyme-inducing drugs, mostly for seizure treatment (53). The reported effects of enzyme inducers such as phenytoin and carbamazepine on bleeding or thromboembolic risk are varied in literature. Multiple studies reported reduced plasma DOAC levels (54, 55) and increased risk of stroke (56) in patients concurrently prescribed enzyme-inducing ASMs and DOACs. On the other hand, a retrospective cohort study

in Taiwan concluded that concomitant use of phenytoin with dabigatran or rivaroxaban led to increased risk of bleeding (57). The latter result appears paradoxical considering that phenytoin is a CYP3A4 and P-glycoprotein inducer which should normally lead to reduced plasma DOAC levels (58, 59). Clinicians prescribing DOACs with first-generation ASMs, many of which are enzyme inducers, should be cognizant of this interaction to prevent anticoagulant treatment failure. Other cardiovascular medications whose concentrations can be lowered by inducers of CYP3A4 include calcium channel blockers such as amlodipine as well as atorvastatin and simvastatin (60, 61).

4.1.2 Second-generation ASMs

4.1.2.1 Clinical effectiveness

Second-generation ASMs include agents such as lamotrigine and topiramate which primarily act on voltage-gated sodium channels; levetiracetam, which appears to act on SV2A receptors; and gabapentin, which primarily acts on high-voltage-associated calcium channels (3, 39).

The efficacy of levetiracetam for primary prophylaxis was investigated in the *Prevention of Epileptic seizures at the Acute phase of intraCerebral Haemorrhage* (PEACH) trial (62) which saw a significant reduction in the number of clinical or electrographic EPSS after supratentorial intracerebral haemorrhage in the treatment group, although the study was interrupted early and thus underpowered ($n = 50$).

Comparison studies generally demonstrate similar effectiveness for secondary prophylaxis but better tolerability in second generation ASMs in comparison with first-generation ASMs. A randomised control trial comparing the effects of levetiracetam (titrated up to 500 mg twice daily) and carbamazepine (titrated up to 300 mg twice daily) in 128 patients with LPSS demonstrated a nonsignificant trend towards a higher seizure-free ratio for patients taking levetiracetam (94% vs. 85%, $p = 0.08$) (63). Another randomised control trial included 64 patients with EPSS or LPSS and compared the effects of lamotrigine (titrated up to 100 mg twice daily) versus carbamazepine (titrated up to 300 mg daily) which demonstrated a nonsignificant trend towards decrease in seizure recurrence within 12 months in the lamotrigine group (64). Of note, levetiracetam and lamotrigine had no significant difference in seizure freedom according to a network meta-analysis based on these studies (65). A more recent network meta-analysis comparing 13 antiseizure medications including both first- and second-generation ASMs in stroke (66) suggested that levetiracetam was among the pharmaceutical agents with the lowest seizure recurrences in comparison to other agents.

4.1.2.2 Safety/tolerability

Levetiracetam and lamotrigine were shown to have the best side-effect profile compared to first-generation agents and with other pharmacological regimens (66) through network meta-analysis, with the most common side effects being fatigue, somnolence, headache, and dizziness (67, 68). Both medications are well-tolerated, with lamotrigine being discontinued due to adverse effects in 9–16% of epilepsy patients (69, 70) and levetiracetam in 15% of patients in a LPSS prospective cohort (71). Notable adverse effects of levetiracetam are behavioural or psychiatric symptoms, which can be observed in 7–14% of patients (72, 73) and should be considered when prescribing to patients with

psychiatric comorbidities or at higher risk of psychiatric symptoms. Given that depression and irritability are common in poststroke populations (61 and 33%, respectively, in one study) (74), it is important to consider this adverse effect. Brivaracetam, an analogue of levetiracetam, is a third-generation medication associated with an improvement in behavioural adverse effects (75) and might be a preferable option for patients at higher risk of psychiatric symptoms.

Rarer side effects of levetiracetam include haematological side effects such as thrombocytopenia, which is usually transient. A causal relationship for thrombocytopenia was established only in around 0.1% of patients in a retrospective study in a general inpatient cohort (76), and thus this adverse effect appears to be rare. In addition, although it has been posited that levetiracetam could cause platelet dysfunction, this has not been replicated in assays on healthy volunteers in a double-blind crossover study (45).

Lamotrigine and levetiracetam were not associated with an increased risk of major congenital malformations compared to patients who were not exposed to ASMs (77). Indeed, multiple studies failed to find any major congenital malformations in children exposed *in utero* and a study from the North American registry finding a malformation rate of 2.03% after monotherapy, which is lower than that of most other ASMs (78).

4.1.2.3 Drug–drug interactions

Second-generation ASMs generally have less serious drug–drug interactions in comparison to first-generation ASMs (79) as they do not induce metabolic enzymes to the same extent. Levetiracetam has a low risk of drug–drug interactions since it mostly circulates unbound to proteins (80) and is primarily excreted renally (75%) (61). Levetiracetam induces P-glycoprotein but not CYP3A4 *in vitro* (81, 82), but does not affect the serum concentration of digoxin, a P-glycoprotein substrate, in healthy volunteers after repeated administration (83). Lamotrigine is metabolised through glucuronidation by UGA1A4 and does not generally interact with other drug-metabolising enzymes. Its apparent clearance increases in the presence of combined oral contraceptives, likely due to the induction of the UDP-glucuronidase system (84). In contrast, lamotrigine did not affect the pharmacokinetics of combined oral contraceptives but reduced the maximum concentration and AUC of levonorgestrel at a clinically insignificant level and much less than phenytoin, carbamazepine, or oxcarbazepine (84). Dose monitoring and adjustment might be prudent for patients who co-administer lamotrigine, oral contraceptives, and valproic acid (see discussion in 4.1.1) to prevent breakthrough seizures. Despite the absence of metabolic enzyme induction, levetiracetam was linked to a higher risk of systemic embolic events and stroke in DOAC-treated patients in some studies (56, 85, 86), although others found no effect (87–89). Other mechanisms, such as pharmacodynamic interactions, could account for such effects but remain unknown, and it is unclear whether the increased stroke risk results from DOAC treatment failure or an intrinsic effect of levetiracetam, as discussed in the previous section (63).

4.1.3 Third-generation ASMs

4.1.3.1 Clinical effectiveness

Third-generation ASMs, such as eslicarbazepine acetate, lacosamide, and perampanel, are being investigated for primary or secondary prophylaxis of post-stroke seizures but there are a limited number of published studies (79, 90, 91). Perampanel was associated with >50% reduction in seizure frequency in 69.1% of LPSS patients

after 3 months (92) and 66.7% in another study, which increased to 83.9% after 12 months (93). Eslicarbazepine acetate achieved >50% seizure reduction in 72.9% of patients after 12 months (94) and lacosamide in 80% of patients (95). Eslicarbazepine acetate and lacosamide were also among those with the lowest seizure recurrence in post-stroke cohorts in a network meta-analysis of 13 ASMs (66).

4.1.3.2 Safety/tolerability

Lacosamide and eslicarbazepine acetate appear to have high tolerability, with retention rates being 91.7 and 90.7% at 12 months respectively, compared to 82.0% for lamotrigine and 77.8% for levetiracetam in a retrospective post-stroke cohort study (96). Perampanel had a similar retention rate of around 92.8–94.8% after 3 months in a post-stroke cohort (92, 93). Common side effects for lacosamide and eslicarbazepine acetate are identical to other sodium channel blockers, such as dizziness, diplopia, vomiting, somnolence, and fatigue (97). Aside from more common adverse effects, perampanel is also associated with a black box warning for psychiatric adverse effects such as aggression, hostility, and suicidal ideation, which are more frequent at 8 or 12 mg compared to placebo with a dose–response relationship (98). Although the evidence is mixed regarding suicidal ideation (97), this side effect is more important in the context of stroke survivors, who have an increased risk of suicide (99).

4.1.3.3 Drug–drug interactions

Eslicarbazepine acetate has been shown to reduce the maximum plasma concentration of simvastatin by 38.88% and AUC by 50.43% when co-administered, likely through the induction of CYP3A4 (100). Perampanel has only weak enzyme inducing properties (61) and lacosamide is not a CYP inducer (101); hence, both drugs minimally affect the concentration of other drugs, although the efficacy of perampanel is significantly reduced in the presence of strong enzyme inducers (102). The role of possible P-glycoprotein induction has also not been investigated. Hence, careful monitoring and appropriate adjustment of statin dose would be prudent for patients on eslicarbazepine acetate, especially if they require high intensity lipid lowering therapy. In addition, avoiding perampanel as add-on therapy to strong enzyme inducers is likely to result in better seizure control.

4.2 Medications for primary prevention of PSS

4.2.1 Statins

4.2.1.1 Clinical effectiveness

Several studies have associated statins with favourable outcomes in PSS for primary prevention. A meta-analysis (103) demonstrated that post-stroke statin use was associated with lower incidence of EPSS and LPSS regardless of whether the stroke was haemorrhagic or ischaemic. Notably, the study demonstrated that pre-stroke statin use was not associated with reduced risk of EPSS or LPSS. While effective for both EPSS and LPSS, statins were shown to be especially effective for the prevention of EPSS in another meta-analysis (104). Lipophilic statins and moderate to high doses per 2013 ACC/AHA guidelines were associated with a reduced risk of LPSS in a retrospective intracerebral haemorrhage cohort study (105). Interestingly, statins were also associated with antiepileptogenic effects in a variety of

animal models and in clinical studies in multiple cohorts with various mechanisms of brain injury, including brain tumours, radiotherapy, and coronary revascularisation in older patients, which suggest their broad antiepileptogenic properties (106). Taken together, the administration of statins after stroke appears to lower the risk of PSS and therefore makes statin a viable agent for primary PSS prevention in addition to its role in managing dyslipidaemia. However, prospective trials are lacking and would be important in establishing the evidence base for the use of statins to prevent PSE.

4.2.1.2 Safety/tolerability

Statins have a good safety profile and were not associated with an increased risk of serious adverse events in a prospective cohort study investigating the effect of high-intensity statins on TIA and stroke patients (107). Persistent elevation of alanine aminotransferase and aspartate aminotransferase was seen more frequently in patients taking statins, although there were no cases of liver failure in this study. Statins are contraindicated in pregnancy and lactation as it is not possible to prove that statins are safe in pregnancy (108).

The discussion on the adverse effects of statin use in stroke patients centres on a possible increase in haemorrhage when statins are used in stroke populations. Indeed, a meta-analysis based on subgroup analyses of the SPARCL and HPS trials (109) showed an increased risk of haemorrhagic stroke when statins were used for secondary prevention in stroke patients. However, a more recent meta-analysis (110) performed on ischaemic stroke patients demonstrated that new statin use was associated with a reduced risk of early intracranial haemorrhage (occurring within 2 weeks of stroke) and did not affect risk of intracranial haemorrhage overall. Trials such as the Statin Use in Intracerebral Haemorrhage Patients (SATURN) trial (111) are ongoing to investigate haemorrhage risk in post-ICH populations. The AHA scientific statement on statin use (108) concludes that while an increased risk of haemorrhage is possible, the absolute risk is small and the benefit in reducing overall stroke and other vascular events outweighs this risk.

4.2.1.3 Drug–drug interactions

Statins are metabolised in many steps, which accounts for their complex drug–drug interactions. Statins are first absorbed in the gut wall, during which P-glycoproteins reduce their concentration in the portal circulation; they are then taken up by hepatic cells by organic anion transporting polypeptide 1B1 (OATP1B1) and subsequently metabolised by CYP enzymes and undergo glucuronidation (112). Agents which induce or inhibit these transporters and metabolic enzymes affect the pharmacokinetics of statins and vice versa, leading to drug–drug interactions.

Most statins (atorvastatin, cerivastatin, simvastatin, lovastatin) are metabolised in the liver by CYP3A4 enzymes and fluvastatin by CYP2C9 (60). Hence, inhibitors of CYP enzymes including cardiovascular drugs such as calcium channel blockers (nifedipine, felodipine, mibefradil, diltiazem, verapamil), other antiarrhythmics (lidocaine) as well as protease inhibitors (indinavir, ritonavir, nelfinavir, saquinavir, etc.), macrolides, and azoles (ketoconazole, itraconazole) are among the drugs which can cause increased plasma concentration of statins and therefore precipitate adverse effects such as myopathy. Conversely, CYP inducers such as troglitazone and rifampicin can reduce plasma doses and require higher doses of statins. Grapefruit juice contains bergamottin, which is an inhibitor of

both CYP3A4 and OAT (112), and should be avoided in patients taking statins.

Statins have also been shown to potentiate the effect of warfarin in some cases, and although the effects are usually clinically negligible, there have been reports of more marked bleeding in a small number of patients (60). Hence, careful monitoring of the INR is needed to adjust warfarin dose to appropriate levels if needed.

4.2.2 ARBs

Angiotensin receptors are upregulated in rat models of epilepsy especially in the hippocampus, and ARBs appear to exert anti-seizure effects through a mechanism partially independent of lowering blood pressure (113). Indeed, TGF- β signalling driven by extravasated albumin after blood–brain barrier compromise is sufficient to induce epileptiform activity, and this signalling is attenuated by the application of losartan (114). A recent retrospective cohort study involving over 2 million patients has shown that angiotensin receptor blockers (ARBs) are associated with reduced incidence of epilepsy (115), although the study was not specifically in a post-stroke setting. Censoring the patients based on stroke incidence increased the magnitude of the protective effect of ARBs, suggesting that ARBs exert their protective effect through other mechanisms than simply reducing the incidence of stroke. However, this association was not seen in patients with preexisting stroke in this study. In a different retrospective cohort study in Taiwan, angiotensin converting enzyme (ACE) inhibitors and ARB use were associated with longer PSE-free survival period especially in people under 85 (116). Further studies on post-stroke cohorts are warranted to reach more definitive conclusions about the potential effects of ARBs on PSS.

4.2.3 Diuretics

Anti-seizure effects of diuretics have been reported from studies investigating the effects of diuretics on neuronal activity in experimental animal models of seizures as well as in patients undergoing resection of epileptic foci (117). The mechanism of action has been posited to be due to carbonic anhydrase inhibition and attenuation of chloride current, which alters glutamate packaging (118). However, while there is evidence to suggest antiseizure effects for diuretics such as hydrochlorothiazide, chlorothiazide, indapamide, furosemide, bumetanide, and acetazolamide, some diuretics such as cyclothiazide and theobromine can be proconvulsant, and others can cause hyponatraemia which can promote seizures when combined with ASMs such as carbamazepine, oxcarbazepine, and eslicarbazepine acetate (117). There is no evidence regarding the use diuretics for primary prevention of PSS.

4.2.4 GLP-1 agonists

A recent meta-analysis on data from 27 randomised clinical trials (119) demonstrated that GLP-1 agonists, but not DPP-4 inhibitors or SGLT2 inhibitors, were associated with reduced incidence of seizures as well as a combined outcome of seizure and epilepsy, although this analysis was not specifically performed in stroke cohorts. Evidence from animal models suggest that possible neuroprotective mechanisms include activation of the cAMP/PKA pathway to promote synaptic growth and repair, reduction of blood–brain barrier leakage, and regulation of neurotransmitter transmission across synapses (120). Further studies investigating the effectiveness of GLP-1 agonists in primary prevention of PSS are warranted.

4.2.5 Eslicarbazepine acetate and perampanel

Phase II clinical trials are currently ongoing to test the efficacy of eslicarbazepine acetate (90) and perampanel (91) for primary anti-epileptogenesis post-stroke. Preliminary results of the eslicarbazepine acetate trial demonstrated a trend towards lower incidence of LPSS in the treatment group compared to the placebo group (121), but analysis results of the full trial have not yet been published.

5 Treatment by stroke aetiology

5.1 Ischaemic stroke

Studies on ischaemic stroke cohorts demonstrated that statins were associated with a decreased incidence of LPSS. In contrast, r-tPA administration did not affect the incidence of PSS according to a systematic review. Regarding secondary prophylaxis, levetiracetam was linked to a 77.1% seizure-free rate at 18 months in patients with ischaemic stroke (71), whereas a small-scale study comparing lamotrigine and carbamazepine showed better efficacy for lamotrigine (64). While the primary protective effect of statins is promising, studies directly comparing the efficacy of different ASMs in ischaemic stroke cohorts are essential for guiding secondary prophylaxis.

5.2 Haemorrhagic stroke

Post-stroke use of statins was associated with lower incidence of LPSS in patients with intracranial haemorrhage (105). Valproic acid did not have a significant effect in prophylaxis of EPSS and LPSS in patients with spontaneous intracerebral haemorrhage (41), and early administration of benzodiazepines was also not associated with lower incidence of seizures in patients with intracerebral haemorrhage (42). Levetiracetam was associated with a lower incidence of EPSS after supratentorial intracerebral haemorrhage in a small study (62). However, two meta-analyses concluded that seizure prophylaxis after intracerebral haemorrhage was not associated with prevention of seizures, both within 14 days of intracerebral haemorrhage onset and at longest follow-up (122, 123). A Cochrane Review in 2013 found no relevant high-quality studies investigating primary and secondary prophylaxis of seizures after subarachnoid haemorrhage (124). The current AHA guidelines do not recommend prophylactic use of ASMs after intracerebral haemorrhage in patients without evidence of seizures (125) and state that randomised evidence do not support routine prophylactic ASM use after aneurysmal SAH (126). However, they suggest that prophylactic ASM use may be reasonable to prevent seizures in patients with aneurysmal SAH if accompanied by high seizure-risk features (presence of MCA aneurysm, high clinical/radiological grade, cortical infarction, or hydrocephalus).

6 Conclusion

Current European and US guidelines do not recommend primary prophylaxis for post-stroke seizure with ASMs in most cases, except for consideration in aneurysmal SAH with high-risk features (Table 2). Although the guidelines diverge in their recommendations for secondary prophylaxis, higher-risk patients, such as those with

recurrent or late seizures and those with haemorrhagic stroke, can be treated with ASMs.

Regarding primary prevention of PSE, there is currently no high-level evidence to support the use of an antiseizure medication or other drugs (e.g., statins) to prevent PSE. Current evidence suggests that blood–brain barrier dysfunction is a contributor to post-stroke epileptogenesis, and agents that promote repair of the barrier, such as statins and losartan, can be beneficial in minimising epileptogenic changes (127). Lipid-lowering therapy with statins is currently a standard of care in the ischemic stroke population because of its role in secondary stroke prevention and also because of its pleiotropic effects, like blood–brain barrier stabilisation (128). In context of PSE, statins appear to be associated with a lower EPSS and PSE risk in stroke patients (103). Losartan and GLP-1 agonists are proposed to prevent epileptogenic activities in the post-stroke patient population (119, 129, 130); however, this needs to be proven in a clinical trial setting. Ongoing drug development trials like the Perampanel for the Prevention of Post-Stroke Epilepsy (PEPSTEP) trial (91) and the Anti-epileptogenic Effects of Eslicarbazepine Acetate (BIA-2093-213) trial (90) will need to be tested in a subsequent phase 3 trial if the results support the use of perampanel or eslicarbazepine acetate to prevent PSE. We have proposed the potential for neuroprotective agents like activated protein C for the primary prevention of PSE, but this needs testing in clinical trials as well (131). Overall, we do not recommend the use of agents specifically for the prevention of PSE due to the lack of strong evidence but note that statins could offer secondary benefits in preventing PSE in addition to their role in lipid control. Although a small potential risk of haemorrhage could be a consideration, we do not recommend withholding statins solely for this concern as the evidence base is conflicted and the benefits outweigh the risks.

Regarding secondary prophylaxis in the PSS population, a recent network meta-analysis revealed weak evidence regarding the choice of ASMs (66). Most of the evidence suggested that some second and third-generation ASMs, such as levetiracetam, lamotrigine, eslicarbazepine acetate, and lacosamide, could be effective with favourable tolerability profiles for secondary prophylaxis of PSS. First-generation ASMs, such as valproic acid and phenytoin, appeared less efficacious and had more adverse effects (66). Based on the limited available evidence, we cautiously suggest that levetiracetam and lamotrigine are preferred agents as they offer a balance of efficacy and tolerability, with the caveat that levetiracetam can affect cognition and mood, and post-stroke populations are already at risk of neuropsychiatric complications. First-generation ASMs have less favourable efficacy and risk profiles and are less preferable for PSE treatment, as was demonstrated in prospective study (132). While preliminary results on third-generation agents are encouraging, larger studies are needed to confirm their efficacy and tolerability.

Overall, the quality of much of the available evidence was low, with only three randomised control trials investigating the efficacy of ASMs on PSS primary prophylaxis or secondary prophylaxis. Currently available evidence overwhelmingly relies on retrospective analyses which may introduce publication selection bias which limits the validity of the conclusions. Inconsistent outcome measures, lack of stratification on seizure timing or stroke aetiology,

TABLE 2 Summary of society guideline recommendations on PSS prophylaxis.

Guidelines		Primary prophylaxis	Secondary prophylaxis
European Stroke Organisation (36)		Weak recommendation against primary prophylaxis	EPSS: only a weak recommendation can be made in favour of secondary prophylaxis, and we suggest not generally employing secondary ASM prophylaxis. LPSS: employing secondary ASM prophylaxis after one unprovoked seizure needs to be considered.
American Heart Association/ American Stroke Association	Ischaemic stroke (136)	Not recommended	Recurrent seizures should be treated in a manner similar to when they occur with acute neurological conditions; ASMs should be selected based on patient characteristics
	Spontaneous intracerebral haemorrhage (125)	Should not be treated prophylactically with ASMs	Recommended to improve functional outcomes and prevent brain injury from prolonged seizures
	Aneurysmal SAH (126)	Benefit of routine administration after aneurysmal SAH not supported by evidence; prophylactic ASM use may be reasonable to prevent seizures in patients with aneurysmal SAH if accompanied by high seizure-risk features	Both EPSS and LPSS warrant longer-term antiseizure medication that should be managed in the postoperative period by a clinician who specialises in seizure management.

and variable study designs were factors which complicated accurate head-to-head comparisons. In addition, noting the differences in the pathophysiology of EPSS and LPSS as well as between haemorrhagic and ischaemic stroke, it is likely that studies with mixed cohort can obscure the treatment effects in each group and introduce heterogeneity bias. Further studies should assess the efficacy of various ASMs stratifying for EPSS and LPSS, as well as by stroke subtype, using standardised outcomes.

In addition, the generation of seizures is multifactorial, with fluctuations in seizure threshold, seizure abnormalities, and the presence of precipitating factors (31). This often makes it difficult to predict the development and cure of epilepsy, making clinical trials of epilepsy prohibitively expensive. Risk stratification scores such as SeLECT 2.0 (24) and CAVE (19), as well as polygenic risk scores (133), aid in the selection of patients who are likely to benefit from ASM treatment. We posit that the development of effective biomarkers to select target populations and to assess their cure or remission is a priority in improving the feasibility of future clinical trials to increase the evidence base for PSS pharmacotherapy (134, 135).

Author contributions

YK: Writing – original draft, Conceptualization, Writing – review & editing, Data curation, Visualization, Investigation. ET: Writing – original draft, Writing – review & editing. TQ: Writing – original draft, Writing – review & editing. HE: Writing – review & editing, Writing – original draft. JZ: Writing – original draft, Writing – review & editing. TT: Writing – review & editing, Writing – original draft. MI: Writing – review & editing, Writing – original draft. LS: Writing – original draft, Writing – review & editing. DL: Writing – original draft, Writing – review & editing. NM: Writing – original draft, Supervision, Conceptualization, Writing – review & editing.

Funding

The author(s) declared that financial support was not received for this work and/or its publication.

Conflict of interest

ET has received personal honoraria for lectures and educational activities from EVER Pharma, Marinus, Arvelle, Angelini, Alexion, Argenx, Medtronic, Biocodex, Bial-Portela & Ca, NewBridge, GL Pharma, GlaxoSmithKline, Boehringer Ingelheim, LivaNova, Eisai, Epilog, UCB, Biogen, Sanofi, STOKe Therapeutics, Jazz Pharmaceuticals, and Rapport; his institution has received research grants from Biogen, UCB Pharma, Eisai, Red Bull, Merck, Bayer, the European Union, FWF Österreichischer Fond zur Wissenschaftsförderung Bundesministerium für Wissenschaft und Forschung, and Jubiläumsfond der Österreichischen Nationalbank. ET is co-Director of the European Consortium for Epilepsy Trials (ECET) and co-founder of PrevEp Inc. JZ has received speaker honoraria for unbranded educations from UCB, Eisai, Orion Pharma, and Angelini pharma and has as an employee of Sahlgrenska University Hospital been an investigator in clinical trials sponsored by Bial, SK life science, GW Pharma, UCB, and Angelini pharma. TT receiving lecturing fees from Daiichi Sankyo, Eisai, UCB Japan, PDR pharma, Eli Lilly, and Nihon Medi-Physics and grant support from PDR pharma and Nihon Medi-Physics. MI receiving lecturing fees from Eisai, UCB Japan, and Eli Lilly.

The remaining authors declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer UA declared a past co-authorship with the author ET to the handling editor.

The authors ET, HE, DL, and NM declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Generative AI statement

The author(s) declared that Generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial

intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

- Ramsay, RE, Rowan, AJ, and Pryor, FM. Special considerations in treating the elderly patient with epilepsy. *Neurology*. (2004) 62:S24. doi: 10.1212/WNL.62.5_suppl_2.S24
- Zelano, J, Holtkamp, M, Agarwal, N, Lattanzi, S, Trinka, E, and Brigo, F. How to diagnose and treat post-stroke seizures and epilepsy. *Epileptic Disord*. (2020) 22:252–63. doi: 10.1684/epd.2020.1159
- Rohracher, A, Kalss, G, Kuchukhidze, G, Neuray, C, Leitingner, M, and Höfler, J. New anti-seizure medication for elderly epilepsy patients - a critical narrative review. *Expert Opin Pharmacother*. (2021) 22:621–34. doi: 10.1080/14656566.2020.1843636
- Lattanzi, S, Trinka, E, Del Giovane, C, Nardone, R, Silvestrini, M, and Brigo, F. Antiepileptic drug monotherapy for epilepsy in the elderly: a systematic review and network meta-analysis. *Epilepsia*. (2019) 60:2245–54. doi: 10.1111/epi.16366
- Trinka, E, and Brigo, F. Antiepileptogenesis in humans: disappointing clinical evidence and ways to move forward. *Curr Opin Neurol*. (2014) 27:227–35. doi: 10.1097/WCO.0000000000000067
- Koepp, M, Trinka, E, Löscher, W, and Klein, P. Prevention of epileptogenesis – are we there yet? *Curr Opin Neurol*. 9900:1256. doi: 10.1097/WCO.0000000000001256
- Löscher, W. The holy grail of epilepsy prevention: preclinical approaches to antiepileptogenic treatments. *Neuropharmacology*. (2020) 167:107605. doi: 10.1016/j.neuropharm.2019.04.011
- Galovic, M, Ferreira-Atuesta, C, Abaira, L, Döhler, N, Sinka, L, Brigo, F, et al. Seizures and epilepsy after stroke: epidemiology, biomarkers and management. *Drugs Aging*. (2021) 38:285–99. doi: 10.1007/s40266-021-00837-7
- Hesdorffer, DC, Benn, EKT, Cascino, GD, and Hauser, WA. Is a first acute symptomatic seizure epilepsy? Mortality and risk for recurrent seizure. *Epilepsia*. (2009) 50:1102–8. doi: 10.1111/j.1528-1167.2008.01945.x
- Kim, HJ, Park, KD, Choi, K-G, and Lee, HW. Clinical predictors of seizure recurrence after the first post-ischemic stroke seizure. *BMC Neurol*. (2016) 16:212. doi: 10.1186/s12883-016-0729-6
- Xu, MY. Poststroke seizure: optimising its management. *Stroke Vascular Neurol*. (2019) 4:48–56. doi: 10.1136/svn-2018-000175
- Fisher, RS, Acevedo, C, Arzimanoglou, A, Bogacz, A, Cross, JH, and Elger, CE. ILAE official report: a practical clinical definition of epilepsy. *Epilepsia*. (2014) 55:475–82. doi: 10.1111/epi.12550
- Schubert, KM, Marson, AG, Trinka, E, and Galovic, M. Epilepsy as a dynamic disease: toward actionable, individualized seizure risk prediction. *Epilepsia*. 1–13. doi: 10.1111/epi.18602
- Lin, R, Yu, Y, Wang, Y, Foster, E, Kwan, P, Lin, M, et al. Risk of post-stroke epilepsy following stroke-associated acute symptomatic seizures. *Front Aging Neurosci*. (2021) 13:2021
- Schubert, KM, Zieglgänsberger, D, Biciatto, G, Abaira, L, Santamarina, E, and Álvarez-Sabin, J. Association of the Timing and Type of acute symptomatic seizures with Poststroke epilepsy and mortality. *Stroke*. (2025) 56:1748–57. doi: 10.1161/STROKEAHA.124.050045
- De Reuck, J, Sieben, A, and Van Maele, G. Characteristics and outcomes of patients with seizures according to the time of onset in relation to stroke. *Eur Neurol*. (2008) 59:225–8. doi: 10.1159/000115635
- Galovic, M, Döhler, N, Erdélyi-Canavese, B, Felbecker, A, Siebel, P, and Conrad, J. Prediction of late seizures after ischaemic stroke with a novel prognostic model (the SeLECT score): a multivariable prediction model development and validation study. *Lancet Neurol*. (2018) 17:143–52. doi: 10.1016/S1474-4422(17)30404-0
- Sinka, L, Abaira, L, Imbach, LL, Zieglgänsberger, D, Santamarina, E, and Álvarez-Sabin, J. Association of Mortality and Risk of epilepsy with type of acute symptomatic seizure after ischemic stroke and an updated prognostic model. *JAMA Neurol*. (2023) 80:605–13. doi: 10.1001/jamaneurol.2023.0611
- Haapaniemi, E, Strbian, D, Rossi, C, Putaala, J, Sipit, T, Mustanoja, S, et al. The CAVE score for predicting late seizures after intracerebral hemorrhage. *Stroke*. (2014) 45:1971–6. doi: 10.1161/STROKEAHA.114.004686
- Schubert, KM, Dasari, V, Oliveira, AL, Tatillo, C, Naeije, G, Strzelczyk, A, et al. The role of electroencephalography in predicting post-stroke seizures and an updated prognostic model (SeLECT-EEG). *Ann Neurol*. (2025) 98:814–25. doi: 10.1002/ana.27301
- Jones, FJS, Sanches, PR, Smith, JR, Zafar, SF, Blacker, D, Hsu, J, et al. Seizure prophylaxis after spontaneous intracerebral hemorrhage. *JAMA Neurol*. (2021) 78:1128–36. doi: 10.1001/jamaneurol.2021.2249
- Abe, S, Tanaka, T, Fukuma, K, Matsubara, S, Motoyama, R, Mizobuchi, M, et al. Intercal epileptiform discharges as a predictive biomarker for recurrence of poststroke epilepsy. *Brain Commun*. (2022) 4:312. doi: 10.1093/braincomms/fcac312
- Tanaka, T, Ihara, M, Fukuma, K, Mishra, NK, Koepp, MJ, Guekht, A, et al. Pathophysiology, diagnosis, prognosis, and prevention of Poststroke epilepsy: clinical and research implications. *Neurology*. (2024) 102:e209450. doi: 10.1212/WNL.0000000000209450
- Meletti, S, Cuccurullo, C, Orlandi, N, Borzi, G, Bigliardi, G, Maffei, S, et al. Prediction of epilepsy after stroke: proposal of a modified SeLECT 2.0 score based on posttreatment stroke outcome. *Epilepsia*. (2024) 65:3234–43. doi: 10.1111/epi.18114
- Bosque-Varela, P, Kuchukhidze, G, Hahn, W, Jünemann, C, Macheegger, L, Möller, L, et al. Peri-ictal imaging abnormalities in non-convulsive status epilepticus: a systematic review and meta-analysis comparing magnetic resonance imaging and computed tomography perfusion. *Epilepsia*. (2025) 1–15. doi: 10.1111/epi.18604
- Gijs, J, Gebeles, A, Vanderlinden, G, Van Laere, K, Radwan, A, Wouters, A, et al. Focal hypermetabolism in suspected non-convulsive status epilepticus. *Epilepsia*. (2026) 4283–4297. doi: 10.1111/epi.18567
- Kim, BS, Lee, S-T, Yun, TJ, Lee, SK, Paeng, JC, Jun, J, et al. Capability of arterial spin labeling MR imaging in localizing seizure focus in clinical seizure activity. *Eur J Radiol*. (2016) 85:1295–303. doi: 10.1016/j.ejrad.2016.04.015
- Koh, DH, Choi, HG, Choi, DS, Shin, HS, Baek, HJ, Kim, YS, et al. Perfusion hyperintensities in patients with seizures: evaluation with arterial spin labeling magnetic resonance imaging within 24 hours after onset. *Investig Magn Reson Imag*. (2024) 28:18–26. doi: 10.13104/imri.2023.0028
- Reddy, SD, Younus, I, Sridhar, V, and Reddy, DS. Neuroimaging biomarkers of experimental Epileptogenesis and refractory epilepsy. *Int J Mol Sci*. (2019) 20:220. doi: 10.3390/ijms20010220
- Mito, R, Cole, JH, Genc, S, Jackson, GD, and Zalesky, A. Towards precision MRI biomarkers in epilepsy with normative modelling. *Brain*. (2025) 148:2247–61. doi: 10.1093/brain/awaf090
- Engel, J Jr, Pitkanen, A, Loeb, JA, Edward Dudek, F, Bertram, EH III, Cole, AJ, et al. Epilepsy biomarkers. *Epilepsia*. (2013) 54:61–9. doi: 10.1111/epi.12299
- Chen, J, Ye, H, Zhang, J, Li, A, and Ni, Y. Pathogenesis of seizures and epilepsy after stroke. *Acta Epileptol*. (2022) 4:2. doi: 10.1186/s42494-021-00068-8
- Tanaka, T, and Ihara, M. Post-stroke epilepsy. *Neurochem Int*. (2017) 107:219–28. doi: 10.1016/j.neuint.2017.02.002
- Brondani, R, de Almeida, AG, Cherubini, PA, Secchi, TL, de Oliveira, MA, Martins, SCO, et al. Risk factors for epilepsy after thrombolysis for ischemic stroke: a cohort study. *Front Neurol*. (2020) 10:256. doi: 10.3389/fneur.2019.01256

35. Tomari, S, Tanaka, T, Ihara, M, Matsuki, T, Fukuma, K, Matsubara, S, et al. Risk factors for post-stroke seizure recurrence after the first episode. *Seizure - European J Epilepsy*. (2017) 52:22–6. doi: 10.1016/j.seizure.2017.09.007
36. Holtkamp, M, Beghi, E, Benninger, F, Kälviäinen, R, Rocamora, R, and Christensen, H. European stroke organisation guidelines for the management of post-stroke seizures and epilepsy. *Eur Stroke J*. (2017) 2:103–15. doi: 10.1177/2396987317705536
37. Huttunen, J, Kurki, MI, von und zu Fraunberg, M, Koivisto, T, Ronkainen, A, Rinne, J, et al. Epilepsy after aneurysmal subarachnoid hemorrhage: a population-based, long-term follow-up study. *Neurology*. (2015) 84:2229–37. doi: 10.1212/WNL.0000000000001643
38. Beghi, E, D'Alessandro, R, Beretta, S, Consoli, D, Crespi, V, Delaj, L, et al. Incidence and predictors of acute symptomatic seizures after stroke. *Neurology*. (2011) 77:1785–93. doi: 10.1212/WNL.0b013e3182364878
39. Sills, GJ, and Rogawski, MA. Mechanisms of action of currently used antiseizure drugs. *Neuropharmacology*. (2020) 168:107966. doi: 10.1016/j.neuropharm.2020.107966
40. Chang, RS, Leung, WCY, Vassallo, M, Sykes, L, Battersby Wood, E, and Kwan, J. Antiepileptic drugs for the primary and secondary prevention of seizures after stroke. *Cochrane Database Syst Rev*. (2022) 2:398. doi: 10.1002/14651858.CD005398.pub4
41. Gilad, R, Boaz, M, Dabby, R, Sadeh, M, and Lampl, Y. Are post intracerebral hemorrhage seizures prevented by anti-epileptic treatment? *Epilepsy Res*. (2011) 95:227–31. doi: 10.1016/j.epilepsyres.2011.04.002
42. van Tuijl, JH, van Raak, EPM, van Oostenbrugge, RJ, Aldenkamp, AP, and Rouhl, RPW. Treatment with diazepam in acute stroke prevents Poststroke seizures: a substudy of the EGASIS trial. *Cerebrovasc Dis*. (2021) 50:216–21. doi: 10.1159/000512799
43. Huang, Y-H, Chi, N-F, Kuan, Y-C, Chan, L, Hu, C-J, Chiou, H-Y, et al. Efficacy of phenytoin, valproic acid, carbamazepine and new antiepileptic drugs on control of late-onset post-stroke epilepsy in Taiwan. *Eur J Neurol*. (2015) 22:1459–68. doi: 10.1111/ene.12766
44. Buoli, M, Serati, M, Botturi, A, and Altamura, AC. The risk of thrombocytopenia during valproic acid therapy: a critical summary of available clinical data. *Drugs R D*. (2018) 18:1–5. doi: 10.1007/s40268-017-0224-6
45. Olaizola, I, Brodde, MF, Kehrel, BE, and Evers, S. The impact of Levetiracetam and valproate on platelet functions—a double-blind, placebo-controlled crossover study. *J Clin Med*. (2023) 12:933. doi: 10.3390/jcm12030933
46. Bambakidis, T, Dekker, SE, Halaweish, I, Liu, B, Nikolian, VC, Georgoff, PE, et al. Valproic acid modulates platelet and coagulation function ex vivo. *Blood Coagul Fibrinolysis*. (2017) 28:479–84. doi: 10.1097/MBC.0000000000000626
47. Nasreddine, W, Atweh, SF, Beydoun, AA, Dirani, M, Nawfal, O, and Beydoun, A. Predicting the occurrence of thrombocytopenia from free valproate levels: a prospective study. *Seizure - European J Epilepsy*. (2022) 94:33–8. doi: 10.1016/j.seizure.2021.11.018
48. Mahmoud, F, and Tampi, RR. Valproic acid-induced parkinsonism in the elderly: a comprehensive review of the literature. *Am J Geriatr Pharmacother*. (2011) 9:405–12. doi: 10.1016/j.amjopharm.2011.09.002
49. Perucca, E. Pharmacological and therapeutic properties of valproate. *CNS Drugs*. (2002) 16:695–714. doi: 10.2165/00023210-200216100-00004
50. Japanese Society of Neurology. Epilepsy Practice Guidelines (2018). Available online at: https://www.neurology-jp.org/guidelinem/tenkan_2018.html (Accessed September 13, 2025).
51. Hanson, J, and Smith, D. Fetal Hydatoin syndrome. *Lancet*. (1976) 307:692.
52. Zaccara, G, and Perucca, E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. *Epileptic Disord*. (2014) 16:409–31. doi: 10.1684/epd.2014.0714
53. Perlman, A, Hochberg-Klein, S, Choshen Cohen, L, Dagan, G, Hirsh-Racah, B, Horwitz, E, et al. Management strategies of the interaction between direct oral anticoagulant and drug-metabolizing enzyme inducers. *J Thromb Thrombolysis*. (2019) 47:590–5. doi: 10.1007/s12399-018-01804-7
54. Sennesael, A-L, Larock, A-S, Hainaut, P, Lessire, S, Hardy, M, Douxfils, J, et al. The impact of strong inducers on direct Oral anticoagulant levels. *Am J Med*. (2021) 134:1295–9. doi: 10.1016/j.amjmed.2021.06.003
55. Wiggins, BS, Northup, A, Johnson, D, and Senfield, J. Reduced anticoagulant effect of dabigatran in a patient receiving concomitant phenytoin. *Pharmacotherapy: the journal of human pharmacology and drug therapy*. (2016) 36:e5–7. doi: 10.1002/phar.1698
56. Gronich, N, Stein, N, and Muskat, M. Association between use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting Oral anticoagulants: nested case-control study. *Clinical Pharmacol Therapeutics*. (2021) 110:1526–36. doi: 10.1002/cpt.2369
57. Chang, S-H, Chou, I-J, Yeh, Y-H, Chiou, M-J, Wen, M-S, and Kuo, C-T. Association between use of non-vitamin K Oral anticoagulants with and without concurrent medications and risk of major bleeding in Nonvalvular atrial fibrillation. *JAMA*. (2017) 318:1250–9. doi: 10.1001/jama.2017.13883
58. Li, A, Li, MK, Crowther, M, and Vazquez, SR. Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: a systematic review. *Thromb Res*. (2020) 194:240–5. doi: 10.1016/j.thromres.2020.08.016
59. Chang, S-H, Wen, M-S, and Kuo, C-F. Drug interactions with non-vitamin K Oral anticoagulants—reply. *JAMA*. (2018) 319:830–1. doi: 10.1001/jama.2017.20854
60. Paoletti, R, Corsini, A, and Bellota, S. Pharmacological interactions of statins. *Atheroscler Suppl*. (2002) 3:35–40. doi: 10.1016/S1567-5688(02)00002-8
61. Zaccara, G, Lattanzi, S, Cincotta, M, and Russo, E. Drug treatments in patients with cardiac diseases and epilepsy. *Acta Neurol Scand*. (2020) 142:37–49. doi: 10.1111/ane.13249
62. Peter-Derex, L, Philippeau, F, Garnier, P, André-Obadia, N, Boulogne, S, Catenois, H, et al. Safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Neurol*. (2022) 21:781–91. doi: 10.1016/S1474-4422(22)00235-6
63. Consoli, D, Bosco, D, Postorino, P, Galati, F, Plastino, M, Perticoni, GF, et al. Levetiracetam versus carbamazepine in patients with late Poststroke seizures: a multicenter prospective randomized open-label study (EpIC project). *Cerebrovasc Dis*. (2012) 34:282–9. doi: 10.1159/000342669
64. Gilad, R, Sadeh, M, Rapoport, A, Dabby, R, Boaz, M, and Lampl, Y. Monotherapy of lamotrigine versus carbamazepine in patients with Poststroke seizure. *Clin Neuropharmacol*. (2007) 30:189–95. doi: 10.1097/WNE.0b013e3180333069
65. Brigo, F, Lattanzi, S, Zelano, J, Bragazzi, NL, Belcastro, V, Nardone, R, et al. Randomized controlled trials of antiepileptic drugs for the treatment of post-stroke seizures: a systematic review with network meta-analysis. *Seizure*. (2018) 61:57–62. doi: 10.1016/j.seizure.2018.08.001
66. Misra, S, Wang, S, Quinn, TJ, Dawson, J, Zelano, J, and Tanaka, T. Antiseizure Medications in Poststroke Seizures. *Neurology*. (2025) 104:e210231. doi: 10.1212/WNL.00000000000210231
67. Beran, RG, Berkovic, SF, Black, AB, Danta, G, Hiersemenzel, R, Schapel, GJ, et al. Efficacy and safety of levetiracetam 1000–3000mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study. *Epilepsy Res*. (2005) 63:1–9. doi: 10.1016/j.epilepsyres.2004.09.005
68. Benbadis, S, Klein, P, Schiemann, J, Diaz, A, Elmoufti, S, and Whitesides, J. Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled phase III randomized, double-blind trials: a post-hoc analysis. *Epilepsy Behav*. (2018) 80:129–34. doi: 10.1016/j.yebeh.2017.12.024
69. Kaminow, L, Schimschock, JR, Hammer, AE, and Vuong, A. Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy. *Epilepsy Behav*. (2003) 4:659–66. doi: 10.1016/j.yebeh.2003.08.033
70. Nieto-Barrera, M, Brozmanova, M, Capovilla, G, Christe, W, Pedersen, B, Kane, K, et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. *Epilepsy Res*. (2001) 46:145–55. doi: 10.1016/S0920-1211(01)00271-6
71. Belcastro, V, Costa, C, Galletti, F, Autuori, A, Pierguidi, L, Pisani, F, et al. Levetiracetam in newly diagnosed late-onset post-stroke seizures: a prospective observational study. *Epilepsy Res*. (2008) 82:223–6. doi: 10.1016/j.epilepsyres.2008.08.008
72. Josephson, CB, Engbers, JDT, Jette, N, Patten, SB, Singh, S, Sajobi, TT, et al. Prediction tools for psychiatric adverse effects after Levetiracetam prescription. *JAMA Neurol*. (2019) 76:440–6. doi: 10.1001/jamaneurol.2018.4561
73. Tao, K, Chen, H, Chen, Y, Gu, Y, and Wang, X. Levetiracetam induces severe psychiatric symptoms in people with epilepsy. *Seizure Eur J Epilepsy*. (2024) 116:147–50. doi: 10.1016/j.seizure.2022.12.002
74. Angelelli, P, Paolucci, S, Bivona, U, Piccardi, L, Ciurli, P, Cantagallo, A, et al. Development of neuropsychiatric symptoms in poststroke patients: a cross-sectional study. *Acta Psychiatr Scand*. (2004) 110:55–63. doi: 10.1111/j.1600-0447.2004.00297.x
75. Steinhoff, BJ, Klein, P, Klitgaard, H, Laloyaux, C, Moseley, BD, Ricchetti-Masterson, K, et al. Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: a systematic review. *Epilepsy Behav*. (2021) 118:939. doi: 10.1016/j.yebeh.2021.107939
76. Sahaya, K, Goyal, MK, Sarwal, A, and Singh, NN. Levetiracetam-induced thrombocytopenia among inpatients: a retrospective study. *Epilepsia*. (2010) 51:2492–5. doi: 10.1111/j.1528-1167.2010.02788.x
77. Veroniki, AA, Cogo, E, Rios, P, Straus, SE, Finkelstein, Y, Kealey, R, et al. Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. *BMC Med*. (2017) 15:95. doi: 10.1186/s12916-017-0845-1
78. Hill, DS, Wlodarczyk, BJ, Palacios, AM, and Finnell, RH. Teratogenic effects of antiepileptic drugs. *Expert Rev Neurother*. (2010) 10:943–59. doi: 10.1586/ern.10.57
79. Zöllner, JP, Schmitt, FC, Rosenow, F, Kohlhasse, K, Seiler, A, Strzelczyk, A, et al. Seizures and epilepsy in patients with ischaemic stroke. *Neurolog Res Prac*. (2021) 3:63. doi: 10.1186/s42466-021-00161-w
80. Radtke, RA. Pharmacokinetics of Levetiracetam. *Epilepsia*. (2001) 42:24–7. doi: 10.1111/j.1528-1167.2001.00005.x
81. Nicolas, J-M, Collart, P, Gerin, B, Mather, G, Trager, W, Levy, R, et al. In vitro evaluation of potential drug interactions with Levetiracetam, a new antiepileptic agent. *Drug Metab Dispos*. (1999) 27:250–4.

82. Lombardo, L, Pellitteri, R, Balazy, M, and Cardile, V. Induction of nuclear receptors and drug resistance in the brain microvascular endothelial cells treated with antiepileptic drugs. *Curr Neurovasc Res.* (2008) 5:82–92. doi: 10.2174/156720208784310196
83. Levy, RH, Ragueneau-Majlessi, I, and Baltes, E. Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. *Epilepsy Res.* (2001) 46:93–9. doi: 10.1016/S0920-1211(01)00253-4
84. Sidhu, J, Job, S, Singh, S, and Philipson, R. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. *Br J Clin Pharmacol.* (2006) 61:191–9. doi: 10.1111/j.1365-2125.2005.02539.x
85. Abou Kaoud, M, Nissan, R, Segev, A, Sabbag, A, Orion, D, and Maor, E. Levetiracetam interaction with direct Oral anticoagulants: a pharmacovigilance study. *CNS Drugs.* (2023) 37:1111–21. doi: 10.1007/s40263-023-01052-1
86. Candeloro, M, Carlin, S, Shapiro, MJ, and Douketis, JD. Drug-drug interactions between direct oral anticoagulants and anticonvulsants and clinical outcomes: a systematic review. *Res Practice Thrombosis Haemostasis.* (2023) 7:100137. doi: 10.1016/j.rpth.2023.100137
87. Huang, Y-T, Chen, T-L, Huang, Y-L, Kuo, C-H, Peng, Y-F, Tang, S-C, et al. Impact of levetiracetam on direct oral anticoagulant level and outcomes among older Asian patients with atrial fibrillation. *Front Pharmacol.* (2025) 16:2025. doi: 10.3389/fphar.2025.1505665
88. Mavri, A, and Ilc, S. The efficacy of direct oral anticoagulants in patients on concomitant treatment with levetiracetam. *Sci Rep.* (2023) 13:9257. doi: 10.1038/s41598-023-33876-8
89. Rota, E, Immovilli, P, Pappalardo, I, Risso, R, Zuccotti, G, Agosti, S, et al. Direct Oral anticoagulants and concomitant anti-seizure medications: a retrospective, case-control study in a real-world setting. *Clin Ther.* (2024) 46:e26–30. doi: 10.1016/j.clinthera.2024.06.002
90. Koepp, MJ, Trinka, E, Mah, Y-H, Bentes, C, Knake, S, Gigli, GL, et al. Antiepileptogenesis after stroke—trials and tribulations: methodological challenges and recruitment results of a phase II study with eslicarbazepine acetate. *Epilepsia Open.* (2023) 8:1190–201. doi: 10.1002/epi4.12735
91. Nicolo, J-P, Chen, Z, Moffat, B, Wright, DK, Sinclair, B, Glarin, R, et al. Study protocol for a phase II randomised, double-blind, placebo-controlled trial of perampanel as an antiepileptogenic treatment following acute stroke. *BMJ Open.* (2021) 11:e043488. doi: 10.1136/bmjopen-2020-043488
92. Yan, C, Yang, T, Sun, Y, Hu, J, Yi, X, Li, C, et al. Efficacy and safety of Perampanel in the treatment of post stroke epilepsy: a multicenter, real-world study. *Heliyon.* (2024) 10:376. doi: 10.1016/j.heliyon.2024.e26376
93. Pascarella, A, Manzo, L, Gasparini, S, Marsico, O, Abelardo, D, Torino, C, et al. Perampanel in post-stroke epilepsy: clinical practice data from the PERampanel as only concomitant antiseizure medication (PEROC) study. *J Neurol Sci.* (2024) 462:123106. doi: 10.1016/j.jns.2024.123106
94. Sales, F, Chaves, J, McMurray, R, Loureiro, R, Fernandes, H, and Villanueva, V. Eslicarbazepine acetate in post-stroke epilepsy: Clinical practice evidence from Euro-Esli. *Acta Neurol Scand.* (2020) 142:563–73. doi: 10.1111/ane.13323
95. Rosenow, F, Brandt, C, Bozorg, A, Dimova, S, Steiniger-Brach, B, Zhang, Y, et al. Lacosamide in patients with epilepsy of cerebrovascular etiology. *Acta Neurol Scand.* (2020) 141:473–82. doi: 10.1111/ane.13230
96. Winter, Y, Uphaus, T, Sandner, K, Klimpe, S, Stuckrad-Barre, S, and Groppa, S. Efficacy and safety of antiseizure medication in post-stroke epilepsy. *Seizure Eur J Epilepsy.* (2022) 100:109–14. doi: 10.1016/j.seizure.2022.07.003
97. LaPenna, P, and Tormoehlen, LM. The pharmacology and toxicology of third-generation anticonvulsant drugs. *J Med Toxicol.* (2017) 13:329–42. doi: 10.1007/s13181-017-0626-4
98. Ettinger, AB, LoPresti, A, Yang, H, Williams, B, Zhou, S, Fain, R, et al. Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel. *Epilepsia.* (2015) 56:1252–63. doi: 10.1111/epi.13054
99. Vyas, MV, Wang, JZ, Gao, MM, and Hackam, DG. Association between stroke and subsequent risk of suicide. *Stroke.* (2021) 52:1460–4. doi: 10.1161/STROKEAHA.120.032692
100. Falcão, A, Pinto, R, Nunes, T, and Soares-da-Silva, P. Effect of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects. *Epilepsy Res.* (2013) 106:244–9. doi: 10.1016/j.eplepsyres.2013.04.009
101. Galgani, A, Palleria, C, Iannone, LF, De Sarro, G, Giorgi, FS, Maschio, M, et al. Pharmacokinetic interactions of clinical interest between direct oral anticoagulants and antiepileptic drugs. *Front Neurol.* (2018) 9:67. doi: 10.3389/fneur.2018.01067
102. Santamarina, E, Bertol, V, Garayoa, V, García-Gomara, MJ, Garamendi-Ruiz, I, Giner, P, et al. Efficacy and tolerability of perampanel as a first add-on therapy with different anti-seizure drugs. *Seizure.* (2020) 83:48–56. doi: 10.1016/j.seizure.2020.09.026
103. Acton, EK, Khazaal, O, Willis, AW, Gelfand, MA, Hennessy, S, Selim, MH, et al. Statins for the prevention of post-stroke seizure and epilepsy development: a systematic review and Meta-analysis. *J Stroke Cerebrovasc Dis.* (2021) 30:106024. doi: 10.1016/j.jstrokecerebrovasdis.2021.106024
104. Fang, J, Tuo, M, Ouyang, K, and Xu, Y. Statin on post-stroke epilepsy: a systematic review and meta-analysis. *J Clin Neurosci.* (2021) 83:83–7. doi: 10.1016/j.jocn.2020.11.023
105. Lin, H-W, Ho, Y-F, and Lin, F-J. Statin use associated with lower risk of epilepsy after intracranial haemorrhage: a population-based cohort study. *Br J Clin Pharmacol.* (2018) 84:1970–9. doi: 10.1111/bcp.13626
106. Hufthy, Y, Bharadwaj, M, Gupta, S, Hussain, D, Joseph, PJS, Khan, A, et al. Statins as antiepileptogenic drugs: analyzing the evidence and identifying the most promising statin. *Epilepsia.* (2022) 63:1889–98. doi: 10.1111/epi.17303
107. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. *N Engl J Med.* (2006) 355:549–59. doi: 10.1056/NEJMoa061894
108. Newman, CB, Preiss, D, Tobert, JA, Jacobson, TA, Page, RL, Goldstein, LB, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. *Arterioscler Thromb Vasc Biol.* (2019) 39:e38–81. doi: 10.1161/ATV.0000000000000073
109. Amarenco, P, and Labreuche, J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. *Lancet Neurol.* (2009) 8:453–63. doi: 10.1016/S1474-4422(09)70058-4
110. Tan, C, Liu, X, Mo, L, Wei, X, Peng, W, Wang, H, et al. Statin, cholesterol, and sICH after acute ischemic stroke: systematic review and meta-analysis. *Neurol Sci.* (2019) 40:2267–75. doi: 10.1007/s10072-019-03995-0
111. Marchina, S, Yeatts, SD, Foster, LD, Janis, S, Shoamanesh, A, Khatri, P, et al. Rationale and Design of the Statin use in intracerebral hemorrhage patients (SATURN) trial. *Cerebrovasc Dis.* (2024) 54:1–277. doi: 10.1159/000538195
112. Kellick, KA, Bottorff, M, and Toth, PP. A clinician's guide to statin drug-drug interactions. *J Clin Lipidol.* (2014) 8:330–46. doi: 10.1016/j.jacl.2014.02.010
113. Gasparini, S, Ferlazzo, E, Sueri, C, Cianci, V, Ascoli, M, Cavalli, SM, et al. Hypertension, seizures, and epilepsy: a review on pathophysiology and management. *Neurol Sci.* (2019) 40:1775–83. doi: 10.1007/s11940-025-00857-3
114. Bar-Klein, G, Cacheaux, LP, Kaminsky, L, Prager, O, Weissberg, I, Schoknecht, K, et al. Losartan prevents acquired epilepsy via TGF- β signaling suppression. *Ann Neurol.* (2014) 75:864–75. doi: 10.1002/ana.24147
115. Wen, X, Otoo, MN, Tang, J, Brothers, T, Ward, KE, Asal, N, et al. Angiotensin receptor blockers for hypertension and risk of epilepsy. *JAMA Neurol.* (2024) 81:866–874. doi: 10.1001/jamaneurol.2024.1714
116. Chang, KC, Lin, CH, and Huang, JA. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers is associated with a reduced risk of Poststroke epilepsy in patients with ischemic stroke. *J Am Heart Assoc.* (2024) 13:e035438. doi: 10.1161/JAHA.124.035438
117. Maa, EH, Kahle, KT, Walcott, BP, Spitz, MC, and Staley, KJ. Diuretics and epilepsy: will the past and present meet? *Epilepsia.* (2011) 52:1559–69. doi: 10.1111/j.1528-1167.2011.03203.x
118. Staley, KJ. Diuretics as antiepileptic drugs: should we go with the flow? *Epilepsy Currents.* (2002) 2:35–8. doi: 10.1111/j.1535-7597.2002.00018.x
119. Sindhu, U, Sharma, A, Zawar, I, and Punia, V. Newer glucose-lowering drugs reduce the risk of late-onset seizure and epilepsy: a meta-analysis. *Epilepsia Open.* (2024) 9:2528–36. doi: 10.1002/epi4.13091
120. Yang, X, Qiang, Q, Li, N, Feng, P, Wei, W, and Hölscher, C. Neuroprotective mechanisms of glucagon-like peptide-1-based therapies in ischemic stroke: an update based on preclinical research. *Front Neurol.* (2022) 13:2022. doi: 10.3389/fneur.2022.844697
121. Koepp, MJET, Yee-Haur, M, Bentes, C, Knake, S, Luigi, GG, Serratos, JM, et al. Eslicarbazepine acetate in stroke patients at high-risk of developing unprovoked seizures: results from an exploratory randomised, double-blind, placebo-controlled phase II anti-epileptogenesis study. *Epilepsia.* (2024) 65:1–508.
122. Tran, QK, Bzhilyanskaya, V, Afridi, LZ, Ahmad, M, Palmer, J, Rehan, MA, et al. Preventing seizure occurrence following spontaneous intracerebral hemorrhage: a systematic review and meta-analysis of seizure prophylaxis. *Seizure - European J Epilepsy.* (2021) 87:46–55. doi: 10.1016/j.seizure.2021.02.029
123. Angriman, F, Tirupakuzhi Vijayaraghavan, BK, Dragoi, L, Lopez Soto, C, Chapman, M, and Scales, DC. Antiepileptic drugs to prevent seizures after spontaneous intracerebral hemorrhage. *Stroke.* (2019) 50:1095–9. doi: 10.1161/STROKEAHA.118.024380
124. Marigold, R, Günther, A, Tiwari, D, and Kwan, J. Antiepileptic drugs for the primary and secondary prevention of seizures after subarachnoid haemorrhage. *Cochrane Database Syst Rev.* (2013) 6:1–13. doi: 10.1002/14651858.CD008710.pub2
125. Greenberg, SM, Ziai, WC, Cordonnier, C, Dowlatsahi, D, Francis, B, Goldstein, JN, et al. 2022 guideline for the Management of Patients with Spontaneous Intracerebral Hemorrhage: a guideline from the American Heart Association/American Stroke Association. *Stroke.* (2022) 53:e282–361. doi: 10.1161/STR.0000000000000407
126. Hoh, BL, Ko, NU, Amin-Hanjani, S, Chou, SH-Y, Cruz-Flores, S, Dangayach, NS, et al. 2023 guideline for the Management of Patients with Aneurysmal Subarachnoid

Hemorrhage: a guideline from the American Heart Association/American Stroke Association. *Stroke*. (2023) 54:e314–70. doi: 10.1161/STR.0000000000000436

127. Meijer, WC, and Gorter, JA. Role of blood–brain barrier dysfunction in the development of poststroke epilepsy. *Epilepsia*. (2024) 65:2519–36. doi: 10.1111/epi.18072

128. Fisher, M, and Moonis, M. Neuroprotective effects of statins: evidence from preclinical and clinical studies. *Curr Treat Options Cardiovasc Med*. (2012) 14:252–9. doi: 10.1007/s11936-012-0174-9

129. Nozaki, T, Ura, H, Takumi, I, Kobayashi, S, Maru, E, and Morita, A. The angiotensin II type I receptor antagonist losartan retards amygdala kindling-induced epileptogenesis. *Brain Res*. (2018) 1694:121–8. doi: 10.1016/j.brainres.2018.05.027

130. Bar-Klein, G, Cacheaux, LP, Kaminsky, L, Prager, O, Weissberg, I, Schoknecht, K, et al. Losartan prevents acquired epilepsy via TGF- β signaling suppression. *Ann Neurol*. (2014) 75:864–75. doi: 10.1002/ana.24147

131. Misra, S, and Mishra, NK. Activated protein C: a potential therapeutic target of post-stroke epileptogenesis. *Epilepsy Behav*. (2025) 164:233. doi: 10.1016/j.yebeh.2024.110233

132. Tanaka, T, Fukuma, K, Abe, S, Matsubara, S, Motoyama, R, Mizobuchi, M, et al. Antiseizure medications for post-stroke epilepsy: a real-world prospective cohort study. *Brain Behav*. (2021) 11:e2330. doi: 10.1002/brb3.2330

133. Clocchiatti-Tuozzo, S, Rivier, CA, Misra, S, Zelano, J, Mazumder, R, Sansing, LH, et al. Polygenic risk of epilepsy and Poststroke epilepsy. *Stroke*. (2024) 55:2835–43. doi: 10.1161/STROKEAHA.124.047459

134. Mishra, NK, Engel, J Jr, Liebeskind, DS, Sharma, VK, Hirsch, LJ, Kasner, SE, et al. International post stroke epilepsy research consortium (IPSERC): a consortium to accelerate discoveries in preventing epileptogenesis after stroke. *Epilepsy Behav*. (2022) 127:502. doi: 10.1016/j.yebeh.2021.108502

135. Mishra, NK, Kwan, P, Tanaka, T, Sunnerhagen, KS, Dawson, J, Zhao, Y, et al. Clinical characteristics and outcomes of patients with post-stroke epilepsy: protocol for an individual patient data meta-analysis from the international post-stroke epilepsy research repository (IPSEERR). *BMJ Open*. (2023) 13:e078684. doi: 10.1136/bmjopen-2023-078684

136. Powers, WJ, Rabinstein, AA, Ackerson, T, Adeoye, OM, Bambakidis, NC, Becker, K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. (2019) 50:e344–418. doi: 10.1161/STR.0000000000000211

137. Beghi, E, Carpio, A, Forsgren, L, Hesdorffer, DC, Malmgren, K, Sander, JW, et al. Recommendation for a definition of acute symptomatic seizure. *Epilepsia*. (2010) 51:671–675. doi: 10.1111/j.1528-1167.2009.02285.x